

A: 58296(18ZC011.DOC)

I have been employed by John Wayne Cancer Institute since July 1, 1991. I am a named inventor of the above-captioned application.

2. It is my understanding that the examiner has objected to my prior declaratory submission regarding the Paulie reference on the grounds that (i) the source and identity of antibody P7A5 is not given, (ii) the methods of antigen preparation are not set forth, (iii) the source and character of antibody C6 is not given and (iv) there are no molecular weight markers for FIG. 1, and the molecular weight marker sizes are not given for FIG. 2 and FIG. 3.

3. First, with respect to antibody P7A5, that antibody is directed to the same antigen as the other antibodies in the Paulie reference. The attached letter from Dr. Paulie confirms this point.

4. Second, the methods by which both batches of UTAA antigen were prepared are as described in the instant specification.

5. Third, the C6 designation is merely a nickname used my laboratory for the antibody designated AD1-40F4 in the instant specification.

6. Fourth, it is submitted that the absence of molecular weight markers is not significant with respect to a comparison of immunologic reactivities. To the extent that the markers may quell any concerns the examiner might have, the markers in FIG. 2 and FIG. 3 are 106, 80, 49.5, 32.5, 27.5, and 18.5 kD, from top to bottom, in the lane marker "STD MW".

7. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

June 11, 1996  
Date

Rishab Gupta  
Dr. Rishab Gupta

# TELEFAX

RG → SH

To: Dr. Rishab K Gupta  
John Wayne Cancer Institute  
2200 Santa Monica Blvd.  
Santa Monica, CA 90404  
Fax: +1 - 310 449 5273

From: Dr. Staffan Paulie  
Dept. of Immunology  
Stockholm University  
S-106 91 Stockholm  
Fax: +46 - 8 157356

Total no. of pages: 1

Dear Dr. Gupta,


I heard from Peter Perlmann that you were interested in testing the antibodies 7E9, 4B5 and 14B11 since you had defined an antigen of similar molecular characteristics. I do not know how likely it is that they actually recognize the same antigen since later analyses of our antibodies have disclosed that they besides their tumor related reactivity also react with endothelial cells and actually are quite useful for staining vessels in different tissues. Furthermore, if I recall correctly we saw very little if any reactivity with melanoma cells.

Anyhow I will of course be happy to supply you with some antibodies and I think it will be interesting to learn about the outcome of your tests. However, if you do not mind I will supply you with the antibody 7E9 plus another antibody P7A5-4. This latter Mab was obtained from a later fusion but is directed to the same antigen.

I was actually just looking for these two hybridomas in our freezers when Peter came and showed me your letter about a week ago. This was quite a coincidence since we have not been growing them for several years. As we have only just taken them up it may take a week or so before we can send supernatants and a little bit longer if you prefer purified antibodies. Please indicate by Fax approximately how much supernatant or purified antibody that you will be needing and we will see to that you get this as soon as possible..

I hope that this is satisfactory to you and I look forward to hearing from you.

Sincerely yours



Staffan Paulie

BEST AVAILABLE COPY